Clinical Trials Browser

Phase EARLY_PHASE1 × OTHER × BO-112 × Clear all

NCT04777708 2023-03-24

BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer

Phase EARLY_PHASE1 Terminated

Gastrointestinal

Carcinoma, Hepatocellular